News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Apr 16, 2021 12:24 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Mar 30, 2021
Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
Mar 30, 2021
Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
Mar 23, 2021
Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Upcoming Events
Mar 30, 2021
8:00 AM EDT
Forma Therapeutics Year-End 2020 Financial Results and Business Update
Learn more
Mar 17, 2021
8:40 AM EDT
Oppenheimer 31st Annual Healthcare Conference
Learn more
Mar 9, 2021
7:00 AM EST
H.C. Wainwright Global Life Sciences Conference
Learn more